Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
NCT Number: NCT02009813
Obesity is an epidemic in Western society and is the biggest risk factor for insulin resistance and type 2 diabetes. The investigators have recently shown that exposure to hyperbaric oxygen (HBO) leads to an increase insulin sensitivity in males ubjects and that this improvement can be measured in all men, not just those with diabetes. The aim of this study is to investigate the time course of this effect and explore the mechanisms involved. The investigators suspect that insulin sensitivity as measured by hyperinsulinaemic-euglycaemic clamp will be increased within the time-frame of one 2-hour hyperbaric oxygen exposure, and that the improvement will be measurable in females as well as males.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Adelaide, South Australia, 5000, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
Time frame: 2 hours
Time frame: 2 hours
Using immuno-histo chemistry (IHC), quantitative plymerase chain reaction (qPCR), Western blot
University of Adelaide
Other
Acronym: HOTAIR2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01361971
Body Weight, Diabetes Mellitus
Adelaide, South Australia, Australia
View Trial DetailsNCT01375491
Body Weight, Diabetes Mellitus
La Jolla, California, United States
View Trial DetailsNCT01617304
Body Weight, Cardiovascular Disease
Frederiksberg, Denmark
View Trial DetailsNCT01434407
Body Weight, Cardiovascular Disease
Copenhagen, Frederiksberg C, Denmark
View Trial Details